Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Iterum Therapeutics (ITRM – Research Report). The associated price target is $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jason McCarthy’s rating is based on Iterum Therapeutics’ strategic positioning and potential market opportunities for its product, Orlynvah. The company has reported a solid financial position with sufficient cash reserves expected to last into 2026, which provides a stable foundation for its operations. Orlynvah, approved for uncomplicated urinary tract infections, holds significant value as the first oral penem antibiotic in the U.S., despite competition from other antibiotics like Blujepta.
The company is focusing on pre-commercialization activities and is considering launching Orlynvah independently in the U.S., which could capitalize on its favorable FDA label covering a broad spectrum of uUTI-causing microbes. The pricing strategy for Orlynvah is competitive within the branded oral antibiotics market, and its potential to address a large patient population, including those with resistant infections, presents a substantial commercial opportunity. Additionally, Iterum’s intellectual property protections and potential for market expansion into regions like the EU further support the Buy rating.
In another report released on May 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.